Efficacy and safety of DALI LDL-apheresis at high blood flow rates: a prospective multicenter study.
Direct adsorption of lipids (DALI) is the first LDL-apheresis method compatible with whole blood. Usually, the blood flow rate is adjusted at 60-80 ml/min, which results in session times of about 2 hr. The present study was performed to test the safety and efficacy of low-density lipoprotein cholesterol (LDL-C) and lipoprotein (a) [Lp(a)] removal by DALI at high blood flow rates in order to reduce treatment time. Thirteen chronic DALI patients in seven centers suffering from hypercholesterolemia (LDL-C 162 +/- 42 mg/dl at baseline) and coronary artery disease were treated on a weekly or biweekly basis by DALI apheresis. The blood flow rate QB was held constant for at least two sessions, respectively, and was increased from 60 to 80, 120, 160, 200, and 240 ml/min. All patients had pre-existing av-fistulas. The anticoagulation was performed by a heparin bolus plus ACD-A at a ratio of citrate:blood ranging from 1:20 to 1:90. Clinically, the sessions were well tolerated and only 26/201 sessions (12%) of the treatments were fraught with minor adverse events. Acute LDL-C reductions (derived from LDL-C levels determined by lipoprotein electrophoresis) averaged 72/66/60/53/50/48% for QB=60/80/120/160/200/240 ml/min. Lp(a) reductions were 68/67/62/60/58/56%, whereas HDL-C losses were < or =10%. Routine blood chemistries and blood cell counts remained in the normal range. Treatment times averaged 142/83/45 min at Qb=60/120/240 ml/min. On average, DALI LDL-apheresis could be performed safely and effectively at high blood flow rates up to at least 120 ml/min in patients with good blood access, which significantly reduced treatment time from 142 to 83 min (-42%).
Wendler
T
T
Department I of Internal Medicine, Nephrology Division, University Hospital, Munich-Grosshadern, Munich, Germany.
Schilling
R
R
Lennertz
A
A
Sodemann
K
K
Kleophas
W
W
Messner
H
H
Riechers
G
G
Wagner
J
J
Keller
C
C
Bosch
T
T
D000327:Adsorption; D000328:Adult; D001781:Blood Component Removal / Q000009:adverse effects / Q000379:methods*; D001783:Blood Flow Velocity; D008078:Cholesterol, LDL / Q000302:isolation & purification; D003324:Coronary Artery Disease / Q000097:blood / Q000628:therapy; D005260:Female; D006801:Humans; D006937:Hypercholesterolemia / Q000097:blood / Q000628:therapy; D017270:Lipoprotein(a) / Q000097:blood / Q000302:isolation & purification; D008077:Lipoproteins, LDL / Q000097:blood / Q000302:isolation & purification*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012449:Safety; D013997:Time Factors
D008078:Cholesterol, LDL; D017270:Lipoprotein(a); D008077:Lipoproteins, LDL